FHTX
Foghorn Therapeutics Inc

620
Mkt Cap
$337.43M
Volume
174,024.00
52W High
$6.95
52W Low
$2.94
PE Ratio
-4.85
FHTX Fundamentals
Price
$5.52
Prev Close
$5.76
Open
$5.56
50D MA
$5.61
Beta
1.75
Avg. Volume
134,818.65
EPS (Annual)
-$1.58
P/B
-3.63
Rev/Employee
$201,803.57
$52.51
Loading...
Loading...
News
all
press releases
Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday
Foghorn Therapeutics (NASDAQ:FHTX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Rating Increased to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised Foghorn Therapeutics to a "strong-buy" rating in a report on Tuesday...
MarketBeat·14d ago
News Placeholder
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings...
MarketBeat·18d ago
News Placeholder
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference
Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation and specifically the BAF (SWI/SNF) chromatin remodeling...
MarketBeat·18d ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.6% - Should You Sell?
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.6% - Should You Sell...
MarketBeat·20d ago
News Placeholder
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One...
MarketBeat·1mo ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1% - Time to Sell?
Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1% - Here's Why...
MarketBeat·2mo ago
News Placeholder
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire VANCOUVER, BC, Jan...
PR Newswire·2mo ago
News Placeholder
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are currently covering the company...
MarketBeat·2mo ago
News Placeholder
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy"
Wall Street Zen raised shares of Foghorn Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest FHTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.